SITC Renal Cell Carcinoma
Immunotherapy Guideline

Webinar Series

SITC is pleased to offer companion educational resources in support of the published Renal Cell Carcinoma CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios.  The educational available features both webinars which are a longer-format recording that takes a deeper look at the guideline recommendations as well as mini-modules which are brief videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG available free and on-demand.

• *Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar
  • Leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma (RCC)" during a live webinar.

• Practical Management Pearls for Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar
  • This advanced webinar explains how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.

• Case Studies in Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar
  • This high-level webinar will include case studies that illustrate execution of guideline recommendations, as well as discussion on difficult topics related to case management, as outlined in the Renal Cell Carcinoma CPG.

• Management of Clear Cell RCC with Large Metastatic Burden
  • Martin H. Voss, MD - Memorial Sloan Kettering Cancer Center, presents a case of a 67-year-old man with metastatic clear cell renal cell carcinoma (ccRCC) with symptomatic endobrachial disease.  This presentation addresses appropriate therapy for patients of poor risk, according to the IMDC model.  Dr. voss also addresses strengths and weaknesses associated with combination therapies, both immunotherapy combinations (IO/IO) and immunotherapy coupled with a tyrosine kinase inhibitor (IO/TKI).  Data from the CheckMate 214 and CLEAR trials are also addressed.  This mini module closes with a panel discussion of factors to consider when choosing an appropriate IO/TKI combination therapy. 
• Management of Toxicities
  • Virginia Seery, MSN, RN, ANP-BC, AOCNP - Beth Israel Deaconess Medical Center presents practical information on the management of toxicities associated with VEGF or mTOR inihibitor monotherapy, nivolumab monotherapy, and combination therapies.  Symptoms and management of skin and liver toxicities and hand foot syndrome are of particular focus.  Ms. Seery emphasizes the importance of a multi-disciplinary approach in managing toxicities with RCC therapies and provides insights on when to hold or continue immunotherapy if a patient exhibits adverse events associated with RCC treatment.  This mini module ends with a panel discussion of patient tolerance of TKIs and how individual patient tolerances may necessitate changes to TKI therapy regimens. 
• Planning Immunotherapy Regimens for Challenging Patient Populations
  • This mini module begins with a case presentation on a patient with metastatic RCC and Crohn's Disease.  Presenter Michael B. Atkins, MD - Georgetown Lombardi Comprehensive Cancer Center addresses the role of anti-PD1 monotherapy for patients with autoimmune conditions or high risk of ipilimumab toxicity as well as data from the HCRN GU16-260 study.  Dr. Atkins also discusses when to stop RCC therapy, using melanoma treatment as a model.  The mini module concludes with a panel discussion of factors to consider when discontinuing IO/TKI combination therapy and when re-starting immunotherapy in the event of RCC recurrence.